PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bcriJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
 
Biochem Res Int. 2012; 2012: 685108.
Published online Apr 11, 2012. doi:  10.1155/2012/685108
PMCID: PMC3432877
A Novel Myosin Essential Light Chain Mutation Causes Hypertrophic Cardiomyopathy with Late Onset and Low Expressivity
Paal Skytt Andersen, 1 Paula Louise Hedley, 1 , 2 Stephen P. Page, 3 Petros Syrris, 3 Johanna Catharina Moolman-Smook, 2 William John McKenna, 3 Perry Mark Elliott, 3 and Michael Christiansen 1 *
1Department of Clinical Biochemistry and Immunology, Statens Serum Institut, 2300S Copenhagen, Denmark
2Department of Biomedical Sciences, University of Stellenbosch, Cape Town, South Africa
3The Heart Hospital, University College London Hospital, London, UK
*Michael Christiansen: mic/at/ssi.dk
Academic Editor: Aldrin V. Gomes
Received December 16, 2011; Accepted February 7, 2012.
Hypertrophic cardiomyopathy (HCM) is caused by mutations in genes encoding sarcomere proteins. Mutations in MYL3, encoding the essential light chain of myosin, are rare and have been associated with sudden death. Both recessive and dominant patterns of inheritance have been suggested. We studied a large family with a 38-year-old asymptomatic HCM-affected male referred because of a murmur. The patient had HCM with left ventricular hypertrophy (max WT 21 mm), a resting left ventricular outflow gradient of 36 mm Hg, and left atrial dilation (54 mm). Genotyping revealed heterozygosity for a novel missense mutation, p.V79I, in MYL3. The mutation was not found in 300 controls, and the patient had no mutations in 10 sarcomere genes. Cascade screening revealed a further nine heterozygote mutation carriers, three of whom had ECG and/or echocardiographic abnormalities but did not fulfil diagnostic criteria for HCM. The penetrance, if we consider this borderline HCM the phenotype of the p.V79I mutation, was 40%, but the mean age of the nonpenetrant mutation carriers is 15, while the mean age of the penetrant mutation carriers is 47. The mutation affects a conserved valine replacing it with a larger isoleucine residue in the region of contact between the light chain and the myosin lever arm. In conclusion, MYL3 mutations can present with low expressivity and late onset.
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant genetic disease caused by mutations in genes which encode sarcomeric proteins [14]. The most frequently affected genes are MYH7 [5], MYBPC3 [6], and TNNT2 [7], coding for the heavy chain of myosin, the myosin-binding protein-C, and troponin T, respectively. More than 200 mutations have been described in these genes. Furthermore, mutations in a number of other genes, for example, mitochondrial genes [8] have been associated with HCM, albeit at a much lower frequency. Among the rare causes of HCM [9] are mutations in MYL3 which encodes the myosin essential light chain (ELC) of the sarcomere [4, 1019]. The ELC is located at the lever arm of the myosin head and stabilises this region (Figure 1) through interaction with the IQ1 motif [20, 21] at aminoacid residues 781–810 [22] in beta myosin. The N-terminus of ELC interacts with actin [23]. Although the precise functional role of ELC has not been defined [24], the protein belongs to the EF-hand family of Ca2+-binding proteins [25] and appears to be involved in force development and fine tuning of muscle contraction [26, 27]. The phosphorylation of a C-terminal serine residue has recently been shown to be of major significance for cardiac contraction [28] in zebra fish.
Figure 1
Figure 1
The structure of the myosin S1 fragment (red) with the essential (ELC) (yellow) and regulatory (RLC) (blue) light chains marked. The structure is based on the X-ray crystallographic data available in the form of the 2MYS pdb file [43].
To date, nine HCM-causing mutations have been described in MYL3. Three missense mutations, p.E56G, p.A57G, and p.R81H, have been found in exon 3 and six, p.G128C p.E143K, p.M149V, p.E152K, p.R154H, and p.H155D in exon 4 [4, 1019] (Figure 2).
Figure 2
Figure 2
The genomic structure of MYL3 with the localization of known disease causing mutations indicated.
The described phenotypes of ELC mutations vary considerably [24], from HCM with an autosomal dominant inheritance and sudden death events, as in p.A57G [13, 17] and p.M149V [10], to a recessive phenotype where only homozygosity was associated with sudden cardiac death [14]. The penetrance is high in middle-aged mutation carriers [24].
Here, we describe a family with a novel MYL3 mutation characterised by low expressivity and late onset of disease.
The proband and family members were subjected to a full clinical evaluation including family history, physical examination, echocardiography, stress test, and 12-lead electrocardiograph (ECG). Disease status for the proband and family members was determined using conventional diagnostic criteria [29, 30]. All family members gave informed consent for genetic testing, while for testing of children, consent was obtained from the parents.
Genomic DNA was extracted from blood samples using a QIAamp DNA purification kit (Qiagen, Germany). DNA from the proband was screened for mutations in the coding regions of MYH7, MYBPC3, TNNT2, TPM1, TNNI3, MYL3, MYL2, ACTC, TCAP, and CSRP3, and exons 3, 7, 14, 18, and 49 of TTN, as detailed in a previous study [5]. The primers and conditions used for screening MYL3 have previously been described [9]. Three-hundred ethnically matched Caucasian controls were used to establish frequencies of genetic variants.
Polyphen2 (http://genetics.bwh.harvard.edu/pph2/) was used to predict the effect of the identified ELC variant (p.V79I) [31].
The modelling of ELC and regulatory domain of MYH7 was performed using PDB Protein Workshop (http://www.rcsb.org/) and the PdB file 1WDC [32]. Homology studies and gene-structure studies were performed using BioEdit vers 7.0.9 [33] and Ensembl (http://www.ensembl.org/).
3.1. Family History
The proband, a 38-year-old obese (BMI = 44) man, was referred for clinical assessment following the identification of a cardiac murmur during routine health check. He was asymptomatic and had never experienced cardiac symptoms, systemic hypertension, or syncope. Echocardiography demonstrated asymmetrical septal ventricular hypertrophy becoming more concentric towards the apex (max WT 21 mm), a resting left ventricular outflow gradient (36 mm Hg) and left atrial dilation (54 mm) (Table 1). Genotyping of 11 sarcomere genes showed him to be heterozygous carrier of a novel missense mutation (c.235G > A), p.V79I, in MYL3, which encodes the ELC of the ventricle. PolyPhen2 prediction of the p.V79I mutation indicated this variant to be “possibly damaging”. The family was offered screening for the mutation and clinical evaluation (see Figure 3 for the pedigree and Table 1 for clinical data on family members).
Figure 3
Figure 3
The pedigree of the examined family, the proband is marked by arrow. He is the only clinically affected (black symbol), + indicates family members who are heterozygous for the p.V79I mutation, − indicates family members who were genetically assessed (more ...)
Examination of the family members resulted in the identification of nine additional heterozygous carriers of the p.V79I mutation, none of whom fulfilled the diagnostic criteria for HCM. Three mutation carriers, see Figure 3 and Table 1, exhibited a borderline phenotype, either based on the presence of an angulated septum in combination with T-wave inversion in AVL on the ECG or diastolic dysfunction in association with left axis deviation (LAD) or LAD and QRS deviation on the ECG. One mutation carrier, a 29-year-old male, exhibited intraventricular conduction defect (IVCD) as an isolated abnormality. The three borderline cases were 58, 55, and 36 years of age, whereas the remaining asymptomatic mutation carriers were 3, 8, 11, 17, 23, and 29 years of age. None of the family members shown in the pedigree had experienced cardiac events or sudden death, but the grandfather of the proband (I-1) was said to have died suddenly and unexpected at the age of 55 years; while a sister (II-6) to the mother had died suddenly and unexpected at the age of 19 years. No information was available as to the cause of these deaths that occurred 4-5 decades ago, and no DNA was available for analysis. As none of the mutation carriers, including the patient with HCM, had any symptoms, severe disease expression, or risk markers, the mutation was considered benign. However, all mutation carriers were offered a follow-up evaluation.
The mutation was not found in 300 controls and had not been registered as a variant in the NCBI SNP databases (dbSNP). Furthermore, there were no clinically affected or borderline cases among the nonmutation carriers.
The p.V79I is a novel variant, which is located in exon 3 in the region where two other HCM-associated missense mutations have previously been identified (Figure 2). Multiple species alignment of MYL3 in seven species indicate that valine is strongly conserved at this position (Figure 4). We examined the location of the p.V79I mutation in the three-dimensional structure of ELC by interpolating the human structure on the structure established for the scallop myosin regulatory domain (Figure 5). The mutation is located on the linker connecting the N- and C-terminal lobes and it is located just two aminoacid residues from the N-C connecting-loop interacting with the first IQ1 motif on myosin (aa 780–810) (Figure 5) [34]. It is possible that the more nonpolar, longer side chain of the isoleucine residue may disrupt interaction of ELC with the positively charged lysine and arginine residues of myosin heavy chain that interface with this ELC region [35].
Figure 4
Figure 4
A homology analysis of the known MYL3 mutations, the valine in residue 79 is highly conserved.
Figure 5
Figure 5
The location of the p.V79I mutation (arrow) in the three-dimensional structure of the regulatory domain of myosin (red) with the essential (ELC) (blue) and regulatory (RLC) (yellow) light chain. The other known mutations in ELC are also marked. It is (more ...)
We have described a patient with mild HCM associated with a novel, dominantly inherited, MYL3 mutation p.V79I. The mutation segregates with disease and is absent in 600 control alleles in a family in which no other mutation was identified in known HCM-associated genes. The phenotypic presentation of the p.V79I mutation is that of classical HCM with asymmetric septal hypertrophy, just as previously described for the p.A57G mutation in two unrelated Korean families [13, 17] but distinct from the rare midcavitary obstruction previously described in patients with p.E143K [14], p.M149V, and p.R154H mutations [15]. Expression was reduced and/or the disease exhibited late occurrence, as nine mutation carriers were asymptomatic and did not fulfil diagnostic criteria for HCM, and no mutation carriers below 35 years of age were affected or even borderline affected. However, four of the mutation carriers, all >35 years of age, exhibited either a borderline phenotype or ICVD. Strictly defined, the mutation has a penetrance of 10%, but as many of the carriers are below 25 years. If we define the phenotype as borderline HCM with a late onset, we can say that all mutation carriers above the age of 35 exhibit this phenotype. However, a more precise definition of the penetrance of disease will depend on followup studies. Unfortunately, it was not possible to obtain more information about the sudden deaths occurring in the two potential mutation carriers, I-1 and II-6, 4-5 decades ago. However, their existence supports that the mutation carriers are offered clinical follow-up.
The part of beta myosin containing the IQ1 motif that interacts with the N-C-loop of ELC harbours a number of HCM-associated mutations, that are, p.S782D [36], p.S782N [35], p.R787H [4], p.L796F [1], and p.A797T [37], supporting the concept that interference with the interaction between ELC and beta myosin results in HCM. Another part of the beta myosin molecule that comes into close contact with ELC is the arginine residue at position 723 [35], and mutations here also result in HCM, for example, p.R723G [38] and p.R723C [39], which further supports the concept that interference with the interaction between ELC and myosin is a pathogenetic substrate of HCM.
Homology modelling suggests that the p.V79I mutation may interfere with the interaction between ELC and myosin heavy chain, a mechanism which is believed to be the cause of disease for a number of reported mutations. Based on this evidence we find it likely that the p.V79I mutation is disease causing. However, it can not be ruled out that the mutation may only be associated with hypertrophy when other triggering conditions are present. In this case, the proband is very obese; obesity has recently been associated with a cardiac hypertrophic response in mice fed a high-fat diet through inactivation of the Foxo3a transcription factor via the Akt pathway [40]. As the cardiac hypertrophic response in the same mouse model is associated with increased caspase activity [40] and caspase has ELC [41] as its primary substrate in the failing heart, obesity may aggravate the development of a hypertrophic phenotype in conditions with reduced ELC functionality. A less specific aggravation of hypertrophy through the leptin-induced cardiac hypertrophic response seen in neonatal rat cardiomyocytes phenotype could also explain that the proband is the only mutation carrier with clinical HCM [42].
The finding of a clinically silent mutation with low expressivity and late onset raises the question of whether it should entail a detailed followup of mutation carriers. However, as most mutations in MYL3 have been associated with sudden death [24], it would seem prudent to conduct a clinical followup of mutation carriers. The potential relation between a MYL3-based genetic predisposition, the hypertrophic phenotype and obesity in the proband should also strengthen the recommendation to the proband to lose weight.
Authors' Contribution
P. Andersen and P. Hedley both contributed equally to the study.
1. Erdmann J, Daehmlow S, Wischke S, et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clinical Genetics. 2003;64(4):339–349. [PubMed]
2. Marian AJ, Salek L, Lutucuta S. Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Medica. 2001;92(6):435–451. [PMC free article] [PubMed]
3. Niimura H, Patton KK, McKenna WJ, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation. 2002;105(4):446–451. [PubMed]
4. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107(17):2227–2232. [PubMed]
5. Andersen PS, Havndrup O, Hougs L, et al. Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives. Human Mutation. 2009;30(3):363–370. [PubMed]
6. Andersen PA, Havndrup O, Bundgaard H, et al. Genetic and phenotypic characterization of mutations in myosin-binding protein C (MYBPC3) in 81 families with familial hypertrophic cardiomyopathy: total or partial haploinsufficiency. European Journal of Human Genetics. 2004;12(8):673–677. [PubMed]
7. Thierfelder L, Watkins H, MacRae C, et al. α-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994;77(5):701–712. [PubMed]
8. Marín-García J, Goldenthal MJ, Filiano JJ. Cardiomyopathy associated with neurologic disorders and mitochondrial phenotype. Journal of Child Neurology. 2002;17(10):759–765. [PubMed]
9. Andersen PS, Havndrup O, Bundgaard H, et al. Myosin light chain mutations in familial hypertrophic cardiomyopathy: phenotypic presentation and frequency in Danish and South African populations. Journal of Medical Genetics. 2001;38(12, article E43) [PMC free article] [PubMed]
10. Arad M, Penas-Lado M, Monserrat L, et al. Gene mutations in apical hypertrophic cardiomyopathy. Circulation. 2005;112(18):2805–2811. [PubMed]
11. Bonne G, Carrier L, Richard P, Hainque B, Schwartz K. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circulation Research. 1998;83(6):580–593. [PubMed]
12. Epstein ND. The molecular biology and pathophysiology of hypertrophic cardiomyopathy due to mutations in the beta myosin heavy chains and the essential and regulatory light chains. Advances in Experimental Medicine and Biology. 1998;453:105–115. [PubMed]
13. Lee WH, Hwang TH, Kimura A, et al. Different expressivity of a ventricular essential myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy. American Heart Journal. 2001;141(2):184–189. [PubMed]
14. Olson TM, Karst ML, Whitby FG, Driscoll DJ. Myosin light chain mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive physiology. Circulation. 2002;105(20):2337–2340. [PubMed]
15. Poetter K, Jiang H, Hassanzadeh S, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nature Genetics. 1996;13(1):63–69. [PubMed]
16. Kaski JP, Syrris P, Esteban MTT, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circulation. 2009;2(5):436–441. [PubMed]
17. Choi JO, Yu CW, Nah JC, et al. Long-term outcome of 4 Korean families with hypertrophic cardiomyopathy caused by 4 different mutations. Clinical Cardiology. 2010;33(7):430–438. [PubMed]
18. Fokstuen S, Munoz A, Melacini P, et al. Rapid detection of genetic variants in hypertrophic cardiomyopathy by custom DNA resequencing array in clinical practice. Journal of Medical Genetics. 2011;48(8):572–576. [PubMed]
19. Garcia-Pavia P, Vzquez ME, Segovia J, et al. Genetic basis of end-stage hypertrophic cardiomyopathy. European Journal of Heart Failure. 2011;13(11):1193–1201. [PubMed]
20. Dominguez R, Freyzon Y, Trybus KM, Cohen C. Crystal structure of a vertebrate smooth muscle myosin motor domain and its complex with the essential light chain: visualization of the pre-power stroke state. Cell. 1998;94(5):559–571. [PubMed]
21. Rayment I, Rypniewski WR, Schmidt-Base K, et al. Three-dimensional structure of myosin subfragment-1: a molecular motor. Science. 1993;261(5117):50–58. [PubMed]
22. Wendel B, Reinhard R, Wachtendorf U, et al. The human β-myosin heavy chain gene: sequence diversity and functional characteristics of the protein. Journal of Cellular Biochemistry. 2000;79(4):566–575. [PubMed]
23. Trayer HR, Trayer IP. Differential binding of rabbit fast muscle myosin light chain isoenzymes to regulated actin. FEBS Letters. 1985;180(2):170–174. [PubMed]
24. Hernandez OM, Jones M, Guzman G, Szczesna-Cordary D. Myosin essential light chain in health and disease. American Journal of Physiology. 2007;292(4):H1643–H1654. [PubMed]
25. Grabarek Z. Structural basis for diversity of the EF-hand calcium-binding proteins. Journal of Molecular Biology. 2006;359(3):509–525. [PubMed]
26. Morano I. Tuning the human heart molecular motors by myosin light chairs. Journal of Molecular Medicine. 1999;77(7):544–555. [PubMed]
27. Morano I. Tuning smooth muscle contraction by molecular motors. Journal of Molecular Medicine. 2003;81(8):481–487. [PubMed]
28. Meder B, Laufer C, Hassel D, et al. A single serine in the carboxyl terminus of cardiac essential myosin light chain-1 controls cardiomyocyte contractility in vivo. Circulation Research. 2009;104(5):650–659. [PubMed]
29. Richardson P, McKenna RW, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93(5):841–842. [PubMed]
30. Ten Cate FJ, Hugenholtz PG, Van Dorp WG, Roelandt J. Prevalence of diagnostic abnormalities in patients with genetically transmitted asymmetric septal hypertrophy. American Journal of Cardiology. 1979;43(4):731–737. [PubMed]
31. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nature Methods. 2010;7(4):248–249. [PMC free article] [PubMed]
32. Houdusse A, Cohen C. Structure of the regulatory domain of scallop myosin at 2 Å resolution: implications for regulation. Structure. 1996;4(1):21–32. [PubMed]
33. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series. 1999;41:95–98.
34. Terrak M, Wu G, Stafford WF, Lu RC, Dominguez R. Two distinct myosin light chain structures are induced by specific variations within the bound IQ motifs—functional implications. The EMBO Journal. 2003;22(3):362–371. [PubMed]
35. Rayment I, Holden HM, Sellers JR, Fananapazir L, Epstein ND. Structural interpretation of the mutations in the β-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(9):3864–3868. [PubMed]
36. Moric E, Mazurek U, Polońska J, et al. Three novel mutations in exon 21 encoding β-cardiac myosin heavy chain. Journal of Applied Genetics. 2003;44(1):103–109. [PubMed]
37. Moolman JC, Brink PA, Corfield VA. Identification of a novel Ala797Thr mutation in exon 21 of the β-myosin heavy chain gene in hypertrophic cardiomyopathy. Human Mutation. 1995;6(2):197–198. [PubMed]
38. Enjuto M, Francino A, Navarro-López F, Viles D, Paré JC, Ballesta AM. Malignant hypertrophic cardiomyopathy caused by the Arg723Gly mutation in β-myosin heavy chain gene. Journal of Molecular and Cellular Cardiology. 2000;32(12):2307–2313. [PubMed]
39. Watkins H, Thierfelder L, Hwang DS, McKenna W, Seidman JG, Seidman CE. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. The Journal of Clinical Investigation. 1992;90(5):1666–1671. [PMC free article] [PubMed]
40. Fang CX, Dong F, Thomas DP, Ma H, He L, Ren J. Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription. American Journal of Physiology. 2008;295(3):H1206–H1215. [PubMed]
41. Moretti A, Weig HJ, Ott T, et al. Essential myosin light chain as a target for caspase-3 in failing myocardium. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(18):11860–11865. [PubMed]
42. Rajapurohitam V, Gan XT, Kirshenbaum LA, Karmazyn M. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circulation Research. 2003;93(4):277–279. [PubMed]
43. Rayment I, Holden HM, Whittaker M, et al. Structure of the actin-myosin complex and its implications for muscle contraction. Science. 1993;261(5117):58–65. [PubMed]
Articles from Biochemistry Research International are provided here courtesy of
Hindawi Publishing Corporation